Free Trial

Barclays' Rating of Iovance Biotherapeutics on 10/13/2026

On October 13, 2026, Barclays updated its outlook on Iovance Biotherapeutics (NASDAQ:IOVA) with the action "Reiterated Rating", keeping a "Overweight" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Barclays PLC

DateCompanyAction
10/13/2026
Vale S.A. stock logo
VALE
Vale
Set Price Target
10/13/2026
Nextpower Inc. stock logo
NXT
Nextpower
Set Price Target
10/13/2026
TELUS Corporation stock logo
TU
TELUS
Set Price Target
10/13/2026
Rogers Communication, Inc. stock logo
RCI
Rogers Communication
Set Price Target
10/13/2026
BCE, Inc. stock logo
BCE
BCE
Set Price Target
10/13/2026
Xylem Inc. stock logo
XYL
Xylem
Reiterated Rating
More Ratings From Barclays PLC